Whittier Trust Co. Invests $62,000 in Haemonetics Co. (NYSE:HAE)

Whittier Trust Co. acquired a new stake in Haemonetics Co. (NYSE:HAE) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 800 shares of the medical instruments supplier’s stock, valued at approximately $62,000.

Several other hedge funds have also added to or reduced their stakes in the business. FMR LLC grew its stake in Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after acquiring an additional 521,640 shares during the period. Wellington Management Group LLP grew its position in shares of Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the period. Raymond James Financial Inc. bought a new stake in Haemonetics during the 4th quarter worth approximately $19,002,000. Thrivent Financial for Lutherans raised its holdings in Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after buying an additional 164,111 shares during the period. Finally, Boston Partners lifted its stake in Haemonetics by 27.5% in the fourth quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock valued at $41,485,000 after buying an additional 115,506 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $64.55 on Tuesday. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The stock has a 50 day moving average of $66.99 and a 200-day moving average of $74.96. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.24 billion, a P/E ratio of 25.41, a P/E/G ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HAE shares. JPMorgan Chase & Co. started coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Raymond James reissued a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Barrington Research decreased their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Finally, Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.